Extended Data Fig. 1: Characterize of lead candidate genes in vitro and in vivo.
From: LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy
a, Schematic of the CRISPR screen. b, Characterization of the proliferation of control or LRRC31-knockout 231BR cells with and without irradiation (6 Gy). c, Schematic diagram of characterization of LRRC31 in mice bearing intracranial 231BR tumors. Cells were engineered to express both luciferase and GFP. d, Changes of tumor volume versus time in mice received subcutaneous inoculation of control or LRRC31-knockout 231BR cells and treated with irradiation (10 Gy). e, f, qRT-PCR analysis of the expression of miR4796 and miR1287 in 231BR cells transduced with lentiviral vectors for expression of the candidate miRNAs or control vector. g, h, WB analysis of the expression of KATNA1 and MYBL2 in 231BR cells transduced with control vector or vectors for overexpression of the indicated gene. Blot is representative of two biologically independent experiments, with similar results obtained. Unprocessed immunoblots are shown in Source Data Extended Data Fig. 1. i-l, Clonogenic analysis of 231BR cells engineered for overexpression of miR4796 (i), miR1287 (j), KATNA1 (g) and MYBL2 (h) 7 days after irradiation. m, Characterization of the proliferation of control or LRRC31-overexpressed 231BR cells with and without irradiation (6 Gy). n, Changes of tumor volume versus time in mice received subcutaneous inoculation of control or LRRC31-overexpressed 231BR cells and treated with irradiation (10 Gy). For b, e, f, i-l, and m, data show the mean ± s.d. (n = 3 biologically independent experiments). For d and n, data show the mean ± s.d. (n = 3 animals). Statistical analysis was performed using the two-tailed, unpaired Student’s t-test.
